JP2017533915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533915A5 JP2017533915A5 JP2017523330A JP2017523330A JP2017533915A5 JP 2017533915 A5 JP2017533915 A5 JP 2017533915A5 JP 2017523330 A JP2017523330 A JP 2017523330A JP 2017523330 A JP2017523330 A JP 2017523330A JP 2017533915 A5 JP2017533915 A5 JP 2017533915A5
- Authority
- JP
- Japan
- Prior art keywords
- ibs
- patients
- hmo
- bacterial overgrowth
- mucosal barrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 28
- 208000012868 Overgrowth Diseases 0.000 claims 12
- 230000001580 bacterial effect Effects 0.000 claims 12
- 230000004682 mucosal barrier function Effects 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 208000024891 symptom Diseases 0.000 claims 9
- 230000000968 intestinal effect Effects 0.000 claims 7
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 claims 7
- IEQCXFNWPAHHQR-YKLSGRGUSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O IEQCXFNWPAHHQR-YKLSGRGUSA-N 0.000 claims 6
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 241000305071 Enterobacterales Species 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 4
- 206010003591 Ataxia Diseases 0.000 claims 3
- 206010012735 Diarrhoea Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 206010000060 Abdominal distension Diseases 0.000 claims 2
- 241000186000 Bifidobacterium Species 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 206010017367 Frequent bowel movements Diseases 0.000 claims 2
- 206010000059 abdominal discomfort Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 210000004251 human milk Anatomy 0.000 claims 2
- 235000020256 human milk Nutrition 0.000 claims 2
- 238000011283 initial treatment period Methods 0.000 claims 2
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 230000009278 visceral effect Effects 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 238000004977 Hueckel calculation Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000033581 fucosylation Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103785A JP7301093B2 (ja) | 2014-10-29 | 2021-06-23 | 過敏性腸症候群の治療のための合成組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470663 | 2014-10-29 | ||
| DKPA201470663 | 2014-10-29 | ||
| PCT/DK2015/050332 WO2016066175A1 (en) | 2014-10-29 | 2015-10-29 | Synthetic composition and method for treating irritable bowel syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103785A Division JP7301093B2 (ja) | 2014-10-29 | 2021-06-23 | 過敏性腸症候群の治療のための合成組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533915A JP2017533915A (ja) | 2017-11-16 |
| JP2017533915A5 true JP2017533915A5 (https=) | 2018-11-08 |
| JP7182872B2 JP7182872B2 (ja) | 2022-12-05 |
Family
ID=55856643
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523330A Active JP7182872B2 (ja) | 2014-10-29 | 2015-10-29 | 過敏性腸症候群の治療のための合成組成物および方法 |
| JP2021103785A Active JP7301093B2 (ja) | 2014-10-29 | 2021-06-23 | 過敏性腸症候群の治療のための合成組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103785A Active JP7301093B2 (ja) | 2014-10-29 | 2021-06-23 | 過敏性腸症候群の治療のための合成組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20160346303A1 (https=) |
| EP (1) | EP3212197A4 (https=) |
| JP (2) | JP7182872B2 (https=) |
| CN (2) | CN107073021A (https=) |
| WO (1) | WO2016066175A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3209673T5 (pl) * | 2014-10-24 | 2023-10-23 | Glycom A/S | Mieszaniny hmo |
| US11040049B2 (en) * | 2014-10-29 | 2021-06-22 | Glycom A/S | Composition comprising HMSs/HMOs and use thereof |
| WO2021111422A1 (en) * | 2019-12-06 | 2021-06-10 | Glycom A/S | Composition comprising 2'-fl and dfl for use in a method for reducing pain |
| EP3212197A4 (en) | 2014-10-29 | 2018-07-11 | Glycom A/S | Synthetic composition and method for treating irritable bowel syndrome |
| US11040050B2 (en) | 2014-10-29 | 2021-06-22 | Glycom A/S | Composition comprising HMSs/HMOs and use thereof |
| CN107846957A (zh) * | 2015-03-05 | 2018-03-27 | 雀巢产品技术援助有限公司 | 用于改善婴儿或幼儿粪便稠度或频率的组合物 |
| ES2886951T3 (es) | 2015-09-14 | 2021-12-21 | Glycom As | Composición para su uso en la modulación de la microbiota |
| US10780103B2 (en) | 2015-10-28 | 2020-09-22 | Glycom A/S | Synthetic composition and method for modulating emotion and mood disorders |
| PL3368046T3 (pl) | 2015-10-28 | 2022-11-28 | Glycom A/S | Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania |
| WO2017144062A1 (en) * | 2016-02-24 | 2017-08-31 | Glycom A/S | Synthetic composition for microbiota modulation |
| ES2924137T3 (es) | 2016-05-05 | 2022-10-04 | Glycom As | Composición que comprende HMOS para uso en el tratamiento de la hipersensibilidad y/o dolor visceral mediados por mastocitos |
| DK3452050T3 (da) * | 2016-05-05 | 2023-02-20 | Glycom As | Composition comprising hmos for the treatment of noninfectious diarrhoea |
| US11224605B2 (en) | 2016-05-19 | 2022-01-18 | Glycom A/S | Synthetic composition |
| MX2018015187A (es) * | 2016-08-04 | 2019-04-24 | Nestec Sa | Composiciones nutricionales con 2fl y lnnt para su uso en la prevencion y/o tratamiento de la diarrea no causada por rotavirus mediante la accion en la disbiosis de la microbiota intestinal. |
| BR112019005329A2 (pt) * | 2016-09-19 | 2019-06-18 | Prolacta Bioscience, Inc. | composições de oligossacarídeos de leite humano purificadas |
| AU2016101768B4 (en) * | 2016-09-28 | 2017-02-02 | Grech, Brian James DR | Treatment for Irritable Bowel Syndrome |
| GB201617519D0 (en) * | 2016-10-14 | 2016-11-30 | Genetic Analysis As | A companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant |
| CN106668034A (zh) * | 2017-01-13 | 2017-05-17 | 华中科技大学同济医学院附属协和医院 | L‑岩藻糖在治疗消化道病变的药品和保健品中应用 |
| WO2018157900A1 (en) * | 2017-03-01 | 2018-09-07 | Glycom A/S | Synthetic composition for microbiota modulation |
| CN111526879A (zh) * | 2017-11-02 | 2020-08-11 | 格礼卡姆股份公司 | 用于减少或预防疲劳和/或改善注意力或专注力的一种或多种hmo |
| EP3716984B1 (en) * | 2017-11-30 | 2024-03-20 | Glycom A/S | Mixture of hmos for treating wheat sensitivity |
| US11602545B2 (en) * | 2017-12-05 | 2023-03-14 | Glycom A/S | Human milk oligosaccharides for treating migraine |
| SG11202004659QA (en) * | 2017-12-08 | 2020-06-29 | Jennewein Biotechnologie Gmbh | Spray-dried sialyllactose |
| WO2019123316A1 (en) * | 2017-12-22 | 2019-06-27 | Glycom A/S | Composition comprising hmos for preventing or reducing nociception |
| CN118452467A (zh) * | 2017-12-22 | 2024-08-09 | 雀巢产品有限公司 | 用途是用于减少婴儿和幼儿的伤害感觉的组合物 |
| CN112423603A (zh) | 2018-07-12 | 2021-02-26 | N·V·努特里奇亚 | 用于改善肠屏障完整性的营养组合物、组合物的制备以及治疗方法 |
| CN113194960A (zh) * | 2018-12-19 | 2021-07-30 | 格礼卡姆股份公司 | 用于治疗使用低fodmap饮食的人的组合物和方法 |
| EP3897663A4 (en) * | 2018-12-21 | 2022-09-07 | Glycom A/S | COMPOSITION AND METHOD FOR PROMOTING HEALING OF THE INTESTINAL BARRIER |
| WO2020250185A1 (en) * | 2019-06-12 | 2020-12-17 | Glycom A/S | Human milk oligosaccharides and compositions thereof for use in preventing, managing or treating symptoms related to migraine |
| ES1240969Y (es) * | 2019-09-18 | 2020-07-30 | Jennewein Biotechnologie Gmbh | Composiciones de cereales que contienen oligosacaridos de la leche humana |
| JP2023501111A (ja) * | 2019-11-14 | 2023-01-18 | グリコム・アクティーゼルスカブ | 腸管における胆汁酸プロファイルを均衡させるための合成組成物 |
| CA3161861A1 (en) * | 2019-11-27 | 2021-06-03 | Glycom A/S | Mixture of hmos |
| IT201900023016A1 (it) * | 2019-12-04 | 2021-06-04 | Alesco Srl | Formulazioni comprendenti un minerale e un polisaccaride, loro composizioni e loro uso nella supplementazione di detto minerale |
| US12533368B2 (en) | 2019-12-06 | 2026-01-27 | Societe Des Produits Nestle S.A. | Compositions for use in the reduction of pain and/or perception of pain in infants and young children |
| AU2020399200A1 (en) * | 2019-12-11 | 2022-06-09 | Société des Produits Nestlé S.A. | Compositions for use in the reduction of nociception and other health benefits in infants and young children |
| EP4255444A4 (en) * | 2020-12-04 | 2024-10-16 | Glycom A/S | Human milk oligosaccharides for use in supporting maturation or improvement of sleeping patterns |
| WO2022124324A1 (ja) * | 2020-12-09 | 2022-06-16 | 株式会社明治 | アシディプロピオニバクテリウム属菌またはその処理物を含んでなる組成物 |
| WO2022155126A1 (en) * | 2021-01-12 | 2022-07-21 | Intrinsic Medicine, Inc. | Methods and compositions for supporting human health during space travel |
| US11712445B2 (en) | 2021-04-30 | 2023-08-01 | Sourabh Kharait | Compositions and methods for improving gastrointestinal function in subjects with renal disease |
| US20250213600A1 (en) * | 2022-03-18 | 2025-07-03 | Meiji Co., Ltd. | Composition for controlling growth of bacteria in the intestinal tract and use thereof |
| CN119584872A (zh) * | 2022-07-21 | 2025-03-07 | 田中惠 | 封入有烟酰胺单核苷酸的用于改善肠道菌群的肠溶性胶囊制剂 |
| WO2025196272A1 (en) * | 2024-03-22 | 2025-09-25 | Dsm Ip Assets B.V. | Combination of mixtures of hmos with mfgm and their use |
| CN120570904A (zh) * | 2025-07-14 | 2025-09-02 | 苏州一兮生物技术有限公司 | 一种用于预防和/或治疗腹泻的组合物及其用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663321A (en) | 1984-06-26 | 1987-05-05 | Merck & Co., Inc. | Triazolobenzodiazepines and pharmaceutical use |
| FR2796082B1 (fr) | 1999-07-07 | 2003-06-27 | Centre Nat Rech Scient | Procede de production d'oligosaccharides |
| WO2004026257A2 (en) | 2002-09-20 | 2004-04-01 | The Board Of Regents Of The University Of Texas System | Treatment of irritable bowel syndrome and related bowel diseases |
| GB0312365D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 3-substituted-1, 4-benzodiazepines |
| AU2005288080B2 (en) * | 2004-09-28 | 2011-10-13 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compound |
| WO2007101862A1 (en) | 2006-03-09 | 2007-09-13 | Centre National De La Recherche Scientifique (Cnrs) | Method of producing sialylated oligosaccharides |
| US20110104282A1 (en) | 2008-04-25 | 2011-05-05 | Karolinska Institutet Innovations Ab | New Therapy of Treatment of the Irritable Bowel Syndrome |
| CN102459294A (zh) | 2009-04-07 | 2012-05-16 | 格礼卡姆股份公司 | 2’-o-岩藻糖基乳糖的合成 |
| ES2651067T3 (es) | 2009-07-06 | 2018-01-24 | Children's Hospital Medical Center | Inhibición de la inflamación con oligosacáridos de la leche |
| EP3241836B1 (en) | 2010-02-19 | 2024-10-30 | Glycom A/S | Polymorph of a tetrasaccharide containing nacetyl-lactosamine |
| WO2011100979A1 (en) | 2010-02-19 | 2011-08-25 | Glycom A/S | Production of 6'-o-sialyllactose and intermediates |
| US9119869B2 (en) * | 2010-04-29 | 2015-09-01 | Ronald J. Shebuski | Mucin derived polypeptides |
| US9200091B2 (en) * | 2010-07-12 | 2015-12-01 | The Regents Of The University Of California | Bovine milk oligosaccharides |
| AU2011278236A1 (en) | 2010-07-16 | 2013-02-07 | Glycom A/S | Derivatization of oligosaccharides |
| EP2454948A1 (en) | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
| CA2822219C (en) * | 2010-12-31 | 2020-12-29 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
| MY191538A (en) * | 2010-12-31 | 2022-06-30 | Abbott Lab | Human milk oligosaccharides to promote growth of beneficial bacteria |
| US20120171166A1 (en) | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota |
| CA2824960A1 (en) * | 2011-02-04 | 2012-08-09 | The Regents Of The University Of California | Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease |
| WO2012113404A1 (en) | 2011-02-21 | 2012-08-30 | Glycom A/S | Novel glycosyl phosphites |
| CN103443113A (zh) | 2011-03-18 | 2013-12-11 | 格力康公司 | 新型含岩藻糖的糖类衍生物的合成 |
| CN103562214B9 (zh) | 2011-05-13 | 2016-12-14 | 格力康公司 | 人乳寡糖(hmo)或其前体的多样化 |
| WO2012155916A1 (en) | 2011-05-13 | 2012-11-22 | Glycom A/S | Manufacture of lacto-n-tetraose |
| CN103562401A (zh) | 2011-05-13 | 2014-02-05 | 格力康公司 | 产生人乳寡糖(hmo)或其前体的方法 |
| EP2760875A4 (en) | 2011-09-30 | 2015-08-26 | Glycom As | SYNTHESIS OF HMO NUCLEAR STRUCTURES |
| WO2013091660A1 (en) | 2011-12-23 | 2013-06-27 | Glycom A/S | A method for obtaining crystalline lacto-n-tetraose and lacto-n-neotetraose precursors and mixtures thereof |
| WO2013139344A1 (en) | 2012-03-20 | 2013-09-26 | Glycom A/S | Synthesis of the trisaccharide 3-o-fucosyllactose and intermediates thereof |
| MY168661A (en) * | 2012-03-27 | 2018-11-28 | Abbott Lab | Methods for modulating cell-mediated immunity using human milk oligosaccharides |
| CN104507483A (zh) * | 2012-04-13 | 2015-04-08 | 波士顿学院理事会 | 益生元组合物及使用方法 |
| JPWO2013161693A1 (ja) * | 2012-04-27 | 2015-12-24 | トライエックス・バイオメディカル株式会社 | 腸内細菌異常増殖による過敏性腸症候群の診断剤及び診断法 |
| WO2015077233A1 (en) | 2013-11-19 | 2015-05-28 | Abbott Laboratories | Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides |
| HK1231398A1 (zh) * | 2014-04-08 | 2017-12-22 | Abbott Laboratories | 使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法 |
| EP3212197A4 (en) | 2014-10-29 | 2018-07-11 | Glycom A/S | Synthetic composition and method for treating irritable bowel syndrome |
| US11040050B2 (en) | 2014-10-29 | 2021-06-22 | Glycom A/S | Composition comprising HMSs/HMOs and use thereof |
| US11040049B2 (en) | 2014-10-29 | 2021-06-22 | Glycom A/S | Composition comprising HMSs/HMOs and use thereof |
| ES2886951T3 (es) | 2015-09-14 | 2021-12-21 | Glycom As | Composición para su uso en la modulación de la microbiota |
| TWI715424B (zh) * | 2020-01-22 | 2021-01-01 | 長春石油化學股份有限公司 | 電解銅箔、電極及包含其之鋰離子電池 |
-
2015
- 2015-10-29 EP EP15854904.8A patent/EP3212197A4/en not_active Withdrawn
- 2015-10-29 CN CN201580058523.4A patent/CN107073021A/zh active Pending
- 2015-10-29 US US15/034,593 patent/US20160346303A1/en not_active Abandoned
- 2015-10-29 WO PCT/DK2015/050332 patent/WO2016066175A1/en not_active Ceased
- 2015-10-29 JP JP2017523330A patent/JP7182872B2/ja active Active
- 2015-10-29 CN CN202211004557.3A patent/CN115364113A/zh active Pending
-
2018
- 2018-02-14 US US15/897,099 patent/US11026959B2/en not_active Expired - Fee Related
-
2021
- 2021-06-07 US US17/341,039 patent/US11833165B2/en active Active
- 2021-06-23 JP JP2021103785A patent/JP7301093B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533915A5 (https=) | ||
| RU2008140167A (ru) | Применение неусвояемых сахаридов для лучшей адаптации младенцев после рождения | |
| Ojetti et al. | The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial | |
| Yasmin et al. | Prebiotics, gut microbiota and metabolic risks: Unveiling the relationship | |
| JP2019163267A5 (https=) | ||
| JP2019048857A5 (https=) | ||
| JP2015523321A5 (https=) | ||
| RU2008119992A (ru) | Предупреждение заболеваний у детей, рожденных посредством кесарева сечения | |
| RU2018107583A (ru) | Питательные композиции с 2fl и lnnt для применения при индукции кишечной микробиоты, которая похожа на кишечную микробиоту младенцев на грудном вскармливании | |
| JP2021504420A5 (https=) | ||
| RU2006144870A (ru) | Синергизм галактоолигосахаридов и полифруктозы | |
| RU2005121665A (ru) | Пребиотические композиции | |
| MX2009010252A (es) | Combinacion simbiotica para mejorar la microbiota intestinal. | |
| RU2013128595A (ru) | Смесь олигосахаридов и продукт питания, содержащий эту смесь, в частности питательная смесь для кормления младенцев | |
| PH12015501309A1 (en) | Human milk oligosaccharides to ameliorate symptoms of stress | |
| RU2013128594A (ru) | Композиция для применения с целью предупреждения и/или лечения состояний кожи и заболеваний кожи | |
| CN105283195A (zh) | 用于治疗过敏患者的感染的合生素组合物 | |
| JP2019508486A5 (https=) | ||
| Licht et al. | Prebiotics for prevention of gut infections | |
| RU2014119930A (ru) | Композиция, предназначенная для применения в стимулировании здорового костного роста и/или в профилактике, и/или терапии заболеваний кости | |
| Horvath et al. | Probiotics, prebiotics, and dietary fiber in the management of functional gastrointestinal disorders | |
| JP2021504421A5 (https=) | ||
| EP3471562A1 (en) | Synthetic compositions comprising human milk oligosaccharides for use the prevention and treatment of disorders | |
| JP2020529431A5 (https=) | ||
| RU2013129518A (ru) | Профилактика или лечение избыточной массы и ожирения у пациентов с диабетом 2 типа |